Phase 2 study of LB-P8 for PSC nets FDA clearance
LISCure Biosciences will launch a Phase 2 trial in the United States to evaluate the safety and effectiveness of LB-P8, its live bacterium candidate…
LISCure Biosciences will launch a Phase 2 trial in the United States to evaluate the safety and effectiveness of LB-P8, its live bacterium candidate…
The U.S. Food and Drug Administration (FDA) has granted fast track status to bepirovirsen, GlaxoSmithKline (GSK)’s candidate treatment for chronic hepatitis B (CHB),…
The U.S. Food and Drug Administration (FDA) has granted investigational new drug (IND) status to GKT831, allowing French pharmaceutical company Genkyotex to advance its drug to a Phase…
NV556 inhibited tumor growth in mice with a liver disease known as non-alcoholic steatohepatitis, or NASH, according to a study by its maker, NeuroVive Pharmaceutical AB.